Human Genome kept by JMP at market outperform

Human Genome Sciences Inc. was reiterated by JMP Securities analyst Charles Duncan at a market outperform rating with a price target on the stock of $21 per share following a meeting with management that "reaffirms transformational news flow from multiple products yet in 2005." Human Genome shares Tuesday were up $0.29, or 2.21%, at $13.40 on volume of 2,041,236 shares versus the three-month running average of 2,411,630 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.